300404 Boji Medical Technology
- 7.08
- -0.21-2.88%
Boji Medical Technology News
Boji Medical Technology (300404.SZ) has the ability to conduct clinical research and development related to synthetic biology.
On June 14, Gelunhui investors asked Boji Medical Technology (300404.SZ) on the investor communication platform, "How many companies has your company cooperated with in synthetic biology projects?" The company replied that the company has the ability to carry out clinical research and development of synthetic biology, and the specific customer information is a commercial secret of the company, which is not convenient to disclose. Please understand.
Boji Medical Technology (300404.SZ): The company's "amino acid glucosamine hydrochloride and sodium chloride complex compound" in the science and technology park has obtained the approval notice for the listing application of active pharmaceutical ingredi
Boji Medical Technology (300404.SZ) announced on June 13 that its wholly-owned subsidiary, Guangzhou Boji Biomedical Technology Park Co., Ltd. (hereinafter referred to as the "Technology Park Company") applied for and obtained the "Approval Notice for the Application of Listing Chemical Raw Materials for Active Pharmaceutical Ingredients" issued by the National Medical Products Administration for the "sulfate glucosamine chloride sodium complex salt". The "sulfate glucosamine chloride sodium complex salt" can be used to produce related dosage form pharmaceuticals and has anti-inflammatory effects.
Boji Pharmaceutical (300404.SZ): Traditional Chinese medicine R&D market boom in 2024 continues in 2023, overall R&D enthusiasm is high
On June 3, Ge Longhui Pharmaceutical (300404.SZ) recently said during a survey receiving institutional investors that the traditional Chinese medicine research and development market boom in 2024 continued in 2023, and overall R&D enthusiasm was high. In particular, the R&D demand for classic traditional Chinese medicine prescriptions and homologous medicines of the same name increased markedly compared to the previous year. Currently, the market is paying a lot of attention to traditional Chinese medicine research and development, and it is expected that it will continue to grow in the future.
Boji Pharmaceutical (300404.SZ): Currently, the company's clinical order prices are stabilizing
On June 3, Ge Longhui Pharmaceutical (300404.SZ) recently said during a survey reception from institutional investors that the company's clinical order prices are currently stabilizing. In recent years, overall CRO competition has been fierce, but the CDE review requirements have continued to rise, and the capacity requirements for CRO companies are getting higher and higher. The sponsor will give priority to cooperating with large CRO companies with stronger contract execution capabilities, richer experience and resources.
Boji Pharmaceutical (300404.SZ): Currently, the company's business is dominated by domestic customers, and an overseas subsidiary has recently been established
On June 3, Ge Longhui Pharmaceutical (300404.SZ) recently said during a survey receiving institutional investors that currently the company's business is dominated by domestic customers, and the main revenue comes from domestic sources. Recently, the company set up an overseas subsidiary, hoping to help domestic companies carry out clinical trials in the US, serve local US companies to carry out early clinical projects, and undertake registration and clinical business from foreign sponsors in China.
Boji Pharmaceuticals (300404.SZ): The amount of new orders in the first quarter increased 135% year-on-year
On June 3, Ge Longhui Pharmaceutical (300404.SZ) recently said during a survey of institutional investors that the company is a professional CRO service provider. The company's revenue and orders have grown rapidly in recent years. In the first quarter of 2024, the company's revenue increased 62.08% year on year, net profit increased 40.67% year on year, and the amount of new orders increased 135% year on year.
Zhitong A Share Sale Restriction Release List|May 31
According to the Zhitong Finance App, the ban on restricted shares of 6 listed companies was lifted on May 31, with a total market value of about 4.797 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted stock type, unbanned shares, Sanhua Intelligent Control 002050, share incentives, 521.43, 10,000 Ruipu Biotech 300119 share incentives, restricted circulation, 697,600 Tongyou Technology 300302 share incentives, limited circulation 8895 million, Jixiang shares 603,399 share incentives, limited circulation, 3.09 million Boji Pharmaceutical 300404 share incentive limited circulation 200,000 Aimu shares 603511
Boji Pharmaceutical (300404.SZ) plans to distribute 0.1 yuan for 10 shares to be deducted from interest on May 27
Boji Pharmaceutical (300404.SZ) announced that the company's 2023 equity distribution plan: to all shareholders for every 10...
Boji Pharmaceutical (300404.SZ): It has mastered a full chain of chemically synthesized peptide research and development technology, not involved in the field of synthetic biology
Gelonghui, May 14 | Boji Pharmaceutical (300404.SZ) said on the investor interactive platform that the company has mastered a full chain of chemically synthesized peptide research and development technology, can provide one-stop CRO services for chemically synthesized peptide products, and is capable of undertaking research and development of innovative peptide drugs and high-end generic drug projects, not involving the field of synthetic biology.
Boji Pharmaceutical (300404.SZ): Currently provides customers with clinical research services for the treatment of diabetes and obesity with “simeglutide injection”
On May 14, Ge Longhui | Boji Pharmaceutical (300404.SZ) said on the investor interactive platform that currently the company provides customers with clinical research services for “simeglutide injections” to treat diabetes and obesity, as well as clinical research services for the treatment of diabetics with cell therapy. Currently, related projects are still being developed and are progressing smoothly.
Boji Pharmaceutical (300404.SZ): 2023 net profit of 243.39 million yuan fell 12.04% year on year
On April 24, Ge Longhui Pharmaceutical (300404.SZ) released its 2023 annual report. Operating revenue was 556 million yuan, up 31.19% year on year, net profit of 243.39 million yuan, down 12.04% year on year. After deducting non-net profit of 1.0017 million yuan, a year-on-year decrease of 24.24%, with basic earnings per share of 0.0657 yuan. A cash dividend of 0.1 yuan is distributed to all shareholders for every 10 shares.
Boji Pharmaceutical (300404.SZ): There are no pertussis-related projects
Gelonghui, April 10 | Boji Pharmaceutical (300404.SZ) said on the investor interactive platform that the company has no projects related to pertussis disease yet, but currently provides pre-clinical and clinical research services for various respiratory infection projects.
Boji Pharmaceutical (300404.SZ): There are plans to establish subsidiaries abroad to expand clinical business abroad
Gelonghui, April 10 | Boji Pharmaceutical (300404.SZ) said on the investor interactive platform that the company has set up subsidiaries abroad and plans to expand clinical business abroad, but currently the company's main business is still domestic, and more than 99% of the company's revenue comes from domestic sources. The company is a professional CRO service provider. The service projects cover various pharmaceutical categories such as chemicals, biopharmaceuticals, traditional Chinese medicine, etc., as well as medical devices. Traditional Chinese medicine research and development services are the company's characteristic business area, and the proportion of traditional Chinese medicine business revenue in the first half of 2023 was 20.15% of total revenue.
Boji Medical Technology Inks 70 Million Yuan Technical Services Deal With Ruianbo Pharmaceutical Technology
Boji Medical Technology (SHE:300404) signed a 69.6 million yuan contract to complete the clinical trial research work on AR882 capsules, the company said in a Monday filing on the Shenzhen Stock Excha
Poinsettia (300723.SZ): The holding subsidiary signs a “Technical Service (Outsourcing) Contract” with Boji Pharmaceuticals
On April 7, Ge Longhui (300723.SZ) announced that its holding subsidiary Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd. signed a “Technical Service (Outsourcing) Contract” with Boji Pharmaceutical Technology Co., Ltd. (“Boji Pharmaceutical”). The total contract amount is RMB 69.63 million (tax included. The total amount of the contract includes the project start-up cost of 2,587 million yuan in the “Early Launch Agreement for Class 1 New Chemical Drug AR882 Capsule Phase III Clinical Trials” signed by both parties in 2023). The contract agreed that Guangzhou Ruianbo commissioned Boji Pharmaceutical to launch “AR882 capsules” to treat primary pain
Boji Pharmaceuticals (300404.SZ): Proposed 2024 Restricted Stock Incentive Plan
GLONGHUI March 19 | Boji Pharmaceutical (300404.SZ) announced the 2024 Restricted Stock Incentive Plan (draft). This incentive plan aims to grant a total of 2.9 million shares to incentive recipients, accounting for approximately 0.7592% of the company's total share capital of 382.052.38 million shares when the draft incentive plan was announced. The incentive shares mentioned above are granted in one time, with no reserved rights. The grant price of restricted shares under this plan is 6.62 yuan/share. The total number of incentive recipients granted under this incentive plan is 23, including core key personnel working in the company (including subsidiaries, same below) at the time of the announcement of this incentive plan.
Boji Medical Technology's Unit Gets Nod to Market Erectile Dysfunction Tablets
Boji Medical Technology's (SHE:300404) unit, Guangzhou Boji Biomedical Technology Park, received approval from China's National Medical Products Administration to register and market its Tadalafil tab
Boji Pharmaceutical (300404.SZ): Subsidiary “Tadalafil Tablets” obtained drug registration certificate
Gelonghui, March 11 | Boji Pharmaceutical (300404.SZ) announced that recently, “tadalafil tablets” declared by Guangzhou Boji Biomedical Technology Park Co., Ltd., a wholly-owned subsidiary of Boji Pharmaceutical Technology Co., Ltd., obtained the “Drug Registration Certificate” approved and issued by the State Drug Administration.
Boji Pharmaceutical (300404.SZ): 0.70% of shares have been repurchased cumulatively
Gelonghui on March 4 | Boji Pharmaceutical (300404.SZ) announced that as of March 1, 2024, the company had repurchased 2,667,000 shares of the company's shares through a dedicated securities account, accounting for 0.70% of the company's current total share capital. The highest transaction price for the repurchase was 7.81 yuan/share, the minimum transaction price was 5.04 yuan/share, and the total transaction amount was RMB 1,50968 million (excluding transaction fees).
Boji Pharmaceutical (300404.SZ): Subsidiary tadalafil tablets obtained drug registration certificate
Gelonghui, March 1 | Boji Pharmaceutical (300404.SZ) announced that recently, “tadalafil tablets” declared by Guangzhou Boji Biomedical Technology Park Co., Ltd., a wholly-owned subsidiary of Boji Pharmaceutical Technology Co., Ltd., obtained two “Drug Registration Certificates” approved and issued by the State Drug Administration. “Tadalafil tablets” are selective, reversible inhibitors of cyclic guanosine phosphate (cGMP) specific phosphodiesterase 5 (PDE5). This product is used to treat male erectile dysfunction and the symptoms and signs of erectile dysfunction combined with benign prostatic hyperplasia.
Analysis
Price Target
No Data
